DURECT Corporation

287 articles with DURECT Corporation

• DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology

  9/9/2019

   DURECT Corporation (Nasdaq: DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology has triggered a $10 million milestone payment from Gilead Sciences, Inc. to DURECT under the license agreement between the companies.

• DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright

  9/4/2019

  DURECT Corporation announced that James E. Brown, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Monday, September 9, 2019 at 11:40 a.m. EDT.

• DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs

  8/1/2019

  DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update.

• DURECT Corporation to Announce Second Quarter 2019 Financial Results on August 1

  7/25/2019

  DURECT Corporation announced that it will report second quarter and six months ended June 30, 2019 financial results and host a conference call after the market close on Thursday, August 1, 2019.

• DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

  7/22/2019

  DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT's SABER® technology

• 

  DURECT and Gilead Collaborate on HIV Therapy in Potential $320 Million+ Deal

  7/22/2019

  “We are pleased to be working on this program with Gilead given their expertise and global leadership in the HIV and HBV fields,” stated James E. Brown, president and chief executive officer of DURECT.

• DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter

  6/27/2019

  DURECT Corporation (Nasdaq: DRRX) today announced it has submitted a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration (FDA) related to POSIMIR® (bupivacaine extended-release solution). 

• DURECT Announces $15 Million Registered Direct Offering

  6/20/2019

  DURECT Corporation announced that it has entered into a securities purchase agreement with certain investors pursuant to which, subject to the terms and conditions expressed therein, the Company agreed to sell and the investors agreed to purchase 29,000,000 shares of common stock of the Company at a price per share of $0.52.

• DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial

  6/18/2019

  DURECT Corporation announced that it has completed dosing the 90 mg cohort of severe AH patients in its ongoing DUR-928 Phase 2a clinical trial, and that after reviewing safety and pharmacokinetic data from the completed cohorts, the Dose Escalation Committee has approved commencement of dosing at the 150 mg level in severe AH patients.

• DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

  5/16/2019

  DURECT Corporation announced that James E. Brown, Chief Executive Officer, and Michael H. Arenberg, Chief Financial Officer, will be participating in the 20th Annual B. Riley FBR Institutional Investor Conference, taking place at the Beverly Hilton Hotel, Beverly Hills, CA May 22-23.

• DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial

  5/8/2019

  Live Webcast of AH Data Presentation and Discussions by KOLs Steven Flamm, M.D., Tarek I. Hassanein, M.D. and Paul Kwo, M.D. Tomorrow, Wednesday, May 8, 2019 at 8:30 a.m. ET

• DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs

  5/7/2019

  Live Webcast of Alcoholic Hepatitis KOL and Earnings Call on Wednesday, May 8th at 8:30 a.m. ET

• DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results

  5/3/2019

  Call will feature discussions by KOLs Steven Flamm, M.D.. Tarek I. Hassanein, M.D., and Paul Kwo, M.D.

• DURECT Appoints Two New Board Members

  4/25/2019

  DURECT Corporation announced the appointment of two new members to its board of directors.

• DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH

  4/1/2019

  DURECT Corporation announced that Michael Arenberg, Chief Financial Officer, will be presenting at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9 at 10:50 a.m. BST / 05.50 a.m. EDT.

• DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)

  3/27/2019

  DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH.

• DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis

  3/21/2019

  DURECT Corporation announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis.

• DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs

  3/7/2019

  DURECT Corporation announced financial results for the three months and year ended December 31, 2018 and provided a corporate update.

• DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter

  2/27/2019

  DURECT Corporation announced it has completed a comprehensive review of its POSIMIR® program and plans to submit a full response to the Complete Response Letter it previously received from U.S. Food and Drug Administration.

• DURECT Corporation to Participate in the Berenberg NASH Day

  2/21/2019

  DURECT Corporation today announced that James E. Brown, President and CEO, and Mike Arenberg, Chief Financial Officer, will be participating in the Berenberg NASH Day, taking place Tuesday, February 26, 2019, at Berenberg's New York City offices.